Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.21.77 extracted from

  • Maeda, H.; Yonou, H.; Yano, K.; Ishii, G.; Saito, S.; Ochiai, A.
    Prostate-specific antigen enhances bioavailability of insulin-like growth factor by degrading insulin-like growth factor binding protein 5 (2009), Biochem. Biophys. Res. Commun., 381, 311-316.
    View publication on PubMed
Search for more literature for 3.4.21.77

Inhibitors

Inhibitors Comment Organism Structure
insulin-like growth factor binding protein 5 PSA induced insulin-like growth factor-mediated type I insulin-like growth factor receptor phosphorylation is inhibited by coincubation with insulin-like growth factor binding protein 5 Homo sapiens
additional information 50 mM EDTA does not inhibit insulin-like growth factor binding protein 5 degradation Homo sapiens
PMSF suppresses the insulin-like growth factor binding protein 5 degradation associated with PSA treatment Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Purification (Commentary)

Purification (Comment) Organism
-
 Homo sapiens

Source Tissue

Source Tissue Comment Organism Textmining
prostate cancer cell
-
 Homo sapiens
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
insulin-like growth factor binding protein 5 + H2O is degraded by PSA in a dose- and time-dependent manner. Under nonreducing conditions is degraded into two fragments with approximate molecular masses of 20 and 15 kDa. Under reducing conditions, is degraded into 4 distinct fragments with approximate molecular masses of 22 kDa, 21 kDa, 18 kDa and 13 kDa Homo sapiens ?
-
 ?

Synonyms

Synonyms Comment Organism
prostate-specific antigen
-
 Homo sapiens
PSA
-
 Homo sapiens

General Information

General Information Comment Organism
physiological function PSA derived from prostate cancer cells can enhance insulin-like growth factor bioavailability in the bone microenvironment of prostate cancer metastasis, thereby permitting prostate cancer survival and malignant progression in the bone microenvironment. Inactive insulin-like growth factor binding protein 5 complex is changed to biologically active insulin-like growth factor through degradation of insulin-like growth factor binding protein 5 by enzymatically active PSA. PSA induces insulin-like growth factor-mediated type I insulin-like growth factor receptor phosphorylation Homo sapiens